Go Pro
OTCMKTS:RDGL

Advanced Medical Isotope Q4 2025 Earnings Report

Advanced Medical Isotope logo
$0.05 0.00 (-1.12%)
As of 08/21/2026 03:59 PM Eastern

Advanced Medical Isotope EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Advanced Medical Isotope Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Advanced Medical Isotope Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Advanced Medical Isotope Earnings Headlines

A Dark Day Is Coming to America
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift in the AI market is approaching, and time is short to prepare. Kaplan points to August 31st as a key turning point for AI investing. He argues the next phase will separate winners from losers, and reveals what he's watching instead of big names like Nvidia.tc pixel
See More Advanced Medical Isotope Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Advanced Medical Isotope? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Advanced Medical Isotope and other key companies, straight to your email.

About Advanced Medical Isotope

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope (OTCMKTS:RDGL) and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

View Advanced Medical Isotope Profile